antibodies - online.com







anti-PLK1 antibody (AA 201-300)

Images



Publication



Overview

Quantity:	100 μL
Target:	PLK1
Binding Specificity:	AA 201-300
Reactivity:	Human
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This PLK1 antibody is un-conjugated
Application:	Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunocytochemistry (ICC), Immunohistochemistry (Frozen Sections) (IHC (fro))

Product Details

Immunogen:	KLH conjugated synthetic peptide derived from human PLK1
Isotype:	IgG
Cross-Reactivity:	Human
Predicted Reactivity:	Mouse,Rat,Dog,Pig,Rabbit
Purification:	Purified by Protein A.

Target Details

Target: PLK1

Target Details

Alternative Name:	PLK1 (PLK1 Products)
Background:	Synonyms: PLK, STPK13, Serine/threonine-protein kinase PLK1, Polo-like kinase 1, PLK-1,
	Serine/threonine-protein kinase 13, PLK1
	Background: PLK1 (polo-like kinase 1) is a member of the serine/threonine protein kinase
	family, cdc5/polo subfamily. PLK1 contains two polo box domains with a predicted molecular
	weight of 68 kDa. PLK1 has been shown to regulate cdc2/cyclin B through phosphorylation and
	activation of cdc25c phosphatase. PLK1 is modified by phosphorylation at Threonine 210.
	PLK1 may also be required for cell division. Depletion of PLK1 results in apoptosis and
	deregulation of expression of PKL1 is correlated with development of many malignancies.
Gene ID:	5347
UniProt:	P53350
Pathways:	Cell Division Cycle, M Phase
Application Details	
Application Notes:	WB 1:300-5000
	ELISA 1:500-1000
	IHC-P 1:200-400
	IHC-F 1:100-500
	IF(IHC-P) 1:50-200
	IF(IHC-F) 1:50-200
	IF(ICC) 1:50-200
	ICC 1:100-500
Restrictions:	For Research Use only
Handling	
Format:	Liquid
Concentration:	1 μg/μL
Buffer:	0.01M TBS(pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
Preservative:	ProClin
Precaution of Use:	This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be
	handled by trained staff only.

Handling


Storage:	4 °C,-20 °C
Storage Comment:	Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
Expiry Date:	12 months

Publications

Product cited in:

Gibori, Eliyahu, Krivitsky, Ben-Shushan, Epshtein, Tiram, Blau, Ofek, Lee, Ruppin, Landsman, Barshack, Golan, Merquiol, Blum, Satchi-Fainaro: "Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer." in: **Nature communications**, Vol. 9, Issue 1, pp. 16, (2018) (PubMed).


Images



Immunohistochemistry (Paraffin-embedded Sections)


Image 1. In vivo antitumor effect of miRNA-siRNA combination. a Trial design for testing miRNA-siRNA combination efficacy in the orthotopic PDAC model. b Tumor growth curves from biweekly fluorescent measurements of tumor-bearing mice treated with APA complexed with miR-34a/PLK1-siRNA, miR-34a/NC-siRNA, PLK1-siRNA/NC-miR, NC-miR/NC-siRNA or PBS (treatments are marked with arrows). (n=6, 7). Data represent mean±SEM. One way ANOVA. c In vivo toxicity via mouse body weight evaluation. Data represent mean±SEM. d An image of a representative mouse from each treatment group 33 days post tumor inoculation showing the difference in tumor fluorescent signal. e Kaplan-Meier survival graph. Log-Rank test, P<0.05 for the combination miR-34a/PLK1-siRNA compared to all other treatment groups. f Effect of miR-34a-PLK1-siRNA combined treatment on proliferation, apoptosis and angiogenesis in MiaPaCa2 orthotopic xenograft tumors. Representative images of H&E, Ki67, cleaved caspase 3 and CD31 immunostaining of tumors from the different treatments,

following 45 days from tumor inoculation, are shown (8-10 fields per slide). Scale bars, 200µm. g Quantification of immunostaining that were shown in f. MVD, microvessel density. Data represent mean±SD. (Student's t-test, *P<0.05, **P<0.01, ***P<0.001) - figure provided by CiteAb. Source: PMID29295989



Immunohistochemistry

Image 2. Formalin-fixed and paraffin embedded human lung carcinoma labeled with Anti-PLK1 Polyclonal Antibody, Unconjugated (ABIN700435) at 1:200 followed by conjugation to the secondary antibody and DAB staining



Immunohistochemistry

Image 3. Formalin-fixed and paraffin embedded human placenta labeled with Anti-PLK1 Polyclonal Antibody, Unconjugated (ABIN700435) at 1:200 followed by conjugation to the secondary antibody and DAB staining